TITLE

HIV gel failure

PUB. DATE
December 2011
SOURCE
New Scientist;12/3/2011, Vol. 212 Issue 2841, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the discontinuation of a U.S. National Institutes of Health (NIH) clinical trial of an HIV prevention therapy that used a vaginal gel formulation of the drug tenofovir after the study did not produce any improvement in infection rates.
ACCESSION #
69610977

 

Related Articles

  • Tenofovir works as pre-exposure prophylaxis against HIV, two studies confirm. Roehr, Bob // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/23/2011, Vol. 343 Issue 7816, p177 

    No abstract available.

  • Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya. Owino, Fredrick; Mandala, Justin; Ambia, Julie; Agot, Kawango; Van Damme, Lut // International Medical Case Reports Journal;2013, Vol. 6, p91 

    Side effects of antiretroviral drug use by HIV-positive patients have been extensively studied; however, there are limited data on the side effects of antiretroviral drugs used as an HIV prophylaxis among healthy, HIV-negative individuals. Here we report on an unusual neuropathy in a 24-year-old...

  • THE HIV YEAR IN REVIEW. ANDERSON-MINSHALL, DIANE // Advocate;Dec2014/Jan2015, Issue 1076, p45 

    A timeline is presented of HIV- and AIDS-related events in 2014 including German scientists who reported extracts from the geranium plant Pelargonium sidoides can block HIV from entering human cells, University of Missouri researchers who reported a molecule in soy sauce, EFdA, could be used to...

  • Interpreting treatment effects in randomised trials. Guyatt, Gordon H.; Juniper, Elizabeth F.; Walter, Stephen D.; Griffith, Lauren E.; Goldstein, Roger S. // BMJ: British Medical Journal (International Edition);02/28/98, Vol. 316 Issue 7132, p690 

    Evaluates several questionnaires on quality of life related to health and discusses the difficulty of interpreting their results. Measures of outcome in clinical trials; Completion of the asthma quality of life questionnaire in a crossover trial; Use of the chronic respiratory questionnaire in...

  • Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir.  // AHFS Consumer Medication Information;Jun2020, p1 

    The combination of elvitegravir, cobicistat, emtricitabine, and tenofovir is used to treat HIV in patients who have not been treated with other medications. Elvitegravir, cobicistat, emtricitabine, and tenofovir is in a class of medications called antivirals. Elvitegravir, emtricitabine, and...

  • Emtricitabine and Tenofovir.  // AHFS Consumer Medication Information;Jun2020, p1 

    The combination of emtricitabine and tenofovir is used along with other medications to treat HIV in patients who are 12 years of age and older. It is also used along with practicing safer sex to help prevent patients, who are at high risk, from getting HIV. Emtricitabine and tenofovir are in a...

  • Effect of Tenofovir on Nucleotidases and Cytokines in HIV-1 Target Cells. Biswas, Nabanita; Rodriguez-Garcia, Marta; Crist, Sarah G.; Shen, Zheng; Bodwell, Jack E.; Fahey, John V.; Wira, Charles R. // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Tenofovir (TFV) has been widely used for pre-exposure prophylaxis of HIV-1 infection with mixed results. While the use of TFV in uninfected individuals for prevention of HIV-1 acquisition is actively being investigated, the possible consequences of TFV exposure for the HIV-target cells and the...

  • Analytic Review of Modeling Studies of ARV Based PrEP Interventions Reveals Strong Influence of Drug-Resistance Assumptions on the Population-Level Effectiveness. Dimitrov, Dobromir; Boily, Marie-Claude; Brown, Elizabeth R.; Hallett, Timothy B. // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Background: Four clinical trials have shown that oral and topical pre-exposure prophylaxis (PrEP) based on tenofovir may be effective in preventing HIV transmission. The expected reduction in HIV transmission and the projected prevalence of drug resistance due to PrEP use vary significantly...

  • FINDING TRU LOVE? REYNOLDS, DANIEL // Advocate;Dec2014/Jan2015, Issue 1076, p43 

    The article discusses increased use of the pre-exposure prophylaxis (PEP) drug Truvada by HIV-negative gay men to prevent HIV infection. Topics include the efforts by founding editor of "Positive Frontiers" magazine, Alex Garner, to educate the LGBT community on Truvada's use for PrEP, efforts...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics